Although patients with NPM1-mutated AML were more likely to relapse (55% vs. 43% of relapses in patients with CBF-mutated AML), a similar proportion of these relapses were detected at the molecular level (64 and 62% of relapses, respectively). Here, CEBPZ is linked to acute myeloid leukemia.